Comorbidity between borderline personality disorder (BPD) and alcohol use disorder (AUD) is high and relevant as alcohol consumption seems to worsen BPD symptomatology. One of the newest treatments for AUD, nalmefene, may be useful to improve BPD symptoms not only indirectly by reducing alcohol consumption but also directly by acting on the opioid system as this system has been related to specific BPD symptoms. This open-label study aimed at evaluating the efficacy of an 8-week nalmefene treatment in reducing alcohol consumption in individuals with BPD and comorbid AUD. A secondary objective was to assess its efficacy in improving general BPD symptomatology and specific behaviors (self injury and binge eating). Eighteen out of the 25 patients with BPD and comorbid AUD enrolled in the study completed all the assessment points. After 8 weeks, a significant reduction was observed in alcohol consumption, BPD global symptomatology, self-injurious behavior, and binge eating. No serious adverse effects were reported; however, five participants experienced mild side effects, resulting in withdrawal from the study in two cases. According to our results, nalmefene may be a safe and effective drug for treating patients with BPD and comorbid AUD. Controlled clinical trials are needed to support our findings.

中文翻译：

---

纳美芬在合并性交界性人格障碍和酒精使用障碍患者中的​​使用：初步报告。

边缘性人格障碍（BPD）和饮酒障碍（AUD）之间的合并症很高，并且相关，因为饮酒似乎会使BPD症状恶化。AUD的最新疗法之一，纳美芬，不仅可以通过减少酒精摄入量间接改善BPD症状，而且还可以通过作用于阿片类药物系统而直接改善BPD症状，因为该系统与特定的BPD症状有关。这项开放性研究旨在评估为期8周的纳美芬治疗在降低BPD和合并症AUD患者饮酒中的功效。次要目标是评估其在改善一般BPD症状和特定行为（自伤和暴饮暴食）方面的功效。在该研究中招募的25名BPD和合并性AUD患者中，有18名完成了所有评估点。8周后，酒精摄入量，BPD总体症状，自残行为和暴饮暴食明显减少。没有严重不良反应的报道。但是，五名参与者出现了轻微的副作用，导致两例退出研究。根据我们的结果，纳美芬可能是治疗BPD和合并症AUD的安全有效的药物。需要对照临床试验来支持我们的发现。